BioSystems International Establishes Licensing Agreement with Lohocla Research Institute to Search for Novel Alcoholism Liver Disease Biomarkers

Published: Jun 11, 2009

PARIS--(BUSINESS WIRE)--Biosystems International (BSI) a biotechnology company focused on the development of novel monoclonal antibody-based diagnostics for cancer and metabolic diseases has established a licensing agreement with the Lohocla Research Corporation for the use of BSI’s patented monoclonal antibody proteomics platform for the discovery of novel alcoholism liver disease biomarkers in blood. Terms of the agreement were not disclosed.

Back to news